Clinical trial · Observational
Gastric-type Endocervical Adenocarcinoma: a Population-based Cohort Study
Surgery Significantly Improves the Prognosis of Locally Advanced Gastric-type Endocervical Adenocarcinoma: a Population-based Cohort Study
NCT06897306CI-TRIAL-00087693completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to collect data of patients with Gastric-type Endocervical Adenocarcinoma from the SEER database, analyze the related prognostic factors and treatment patterns of Gastric-type Endocervical Adenocarcinoma, and explore the impact of surgical treatment on the prognosis of locally advanced Gastric-type Endocervical Adenocarcinoma.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Cervical Carcinoma | Cervical Carcinoma | CURATED_BROADER | 0.78 |
| Surgery | — | UNRESOLVED | — |
| Therapy | — | UNRESOLVED | — |
| Uterine Cervical Neoplasms | Cervical Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival (OS)
- timeFrame
- The time from diagnosis to death of the patient，Assessed up to 227 months
- description
- The time from diagnosis to death of the patient.
Secondary outcomes (1)
- measure
- Vital status recode(study cutoff used)
- timeFrame
- up to 227 months
- description
- Any patient that dies after the follow-up cut-off date is recoded to alive as of the cut-off date.
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with Gastric - type Endocervical Adenocarcinoma were identified using the SEER database and SEER\*Stat 8.4.2 software. The search scope was the "SEER Research Plus Data, 17 Registries, Nov 2021 sub (2000 - 2019)" database. The screening criteria included "Site and Morphology, Analytic Behavior Recode = Malignant" and "Site and Morphology, ICD - O - 3 / WHO 2008 Recode Site = Cervix". Patients with Gastric - type Endocervical Adenocarcinoma in the database were selected. Exclusion Criteria: * Patients with a survival time of 0 or unknown.
References
Publications (0)
Data not yet available
No reference posted for this study.